Table 5.

Duration of clinical inertia: time patients remained on their last oral treatment regimen with inadequate glycaemic control prior to GLP-1 RA initiation

Consecutive months	Patient data reported by physicians categorized into three groups			Total sample [N = 1063]a	p-value for group comparison	Pairwise comparisonb
	Group 1: diabetes specialists [N = 428]a	Group 2: GPwSIs [N = 205]a	Group 3: GPs [N = 430]a
With HbA1c cut-off of  > 7.0% for inadequate glycaemic control
Mean (SD)	16.7 (16.6)	20.1 (16.3)	20.4 (17.1)	18.9 (16.8)	0.0023c	A: 0.1151 B: 0.0139 C: 0.9983
Estimated median from KM (95% CI)	11.0 (9.00–12.10)	16.2 (13.10–20.60)	17.0 (14.30–19.40)	13.5 (12.40–15.50)	0.0428d	A: 0.2312 B: 0.0383 C: 0.4986
Minimum–maximume	0.0–59.8	0.0–58.0	0.0–59.6	0.0–59.8
With HbA1c cut-off of > 7.5% for inadequate glycaemic control
Mean (SD)	14.1 (15.3)	17.9 (15.8)	17.3 (16.5)	16.1 (16.0)	0.0030c	A: 0.0480 B: 0.0381 C: 0.9725
Estimated median from  KM (95% CI)	8.1 (6.70–10.20)	13.7 (11.90–17.70)	12.6 (10.90–14.30)	11.2 (10.00–12.10)	0.0167d	A: 0.0468 B: 0.0248 C: 0.8417
Minimum–maximume	0.0–59.1	0.0–58.0	0.0–59.5	0.0–59.5

GLP-1 glucagon-like peptide-1, GPwSIs general practitioners with a special interest in diabetes, GPs general practitioners with no special interest in diabetes, RA receptor agonist, SD standard deviation, CI confidence interval, KM Kaplan–Meier, ANOVA analysis of variance, HbA1c glycated haemoglobin

^aNumber of eligible patients with an oral treatment regimen within the 5 years prior to GLP-1 initiation (specialists: 428 of 437; GPwSIs: 205 of 216; GPs: 430 of 443)

^bPairwise comparisons: A: group 1 vs. group 2; B: group 1 vs. group 3; C: group 2 vs. group 3

^cFrom ANOVA with Scheffe’s post hoc pairwise comparisons

^dFrom the log-rank test

^eMinimum was 0.0 years due to rounding; however, all patients had at least 1 week between diagnosis and GLP-1 RA initiation